

IDS - 03/21/2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/604,944
				Filing Date	August 28, 2003
				First Named Inventor	I. Bentwich
				Group Art Unit	1631
				Examiner Name	Dejong, Eric S.
Sheet	1	of	3	Attorney Docket Number	06087.0300.CPUS08

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
ED	641	Elbashir, S., et al., "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells," Nature, Vol. 411, pp. 494-498 (2001)	
ED	899	Carrington, J., et al., "Role of MicroRNAs in Plant and Animal Development," Science, Vol. 301, pp. 336-338 (2003)	
ED	942	Coburn, Glen, et al., "Potent and Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by RNA Interference," Journal of Virology, Vol. 76, No. 18, pp. 9225-9231 (2002)	
ED	1035	Hutvagner, G., et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the <i>let-7</i> Small Temporal RNA," Science, Vol. 293, pp. 834-838 (2001)	
ED	1081	Mallory, A., et al., "A Viral Suppressor of RNA Silencing Differentially Regulates the Accumulation of Short Interfering RNAs and Micro-RNAs in Tobacco," PINAS, Vol. 99, No. 23, pp. 15228-15233 (2002)	
ED	1086	Li, H., et al., "Induction and Suppression of RNA Silencing by an Animal Virus," Science, Vol. 296, pp. 1319-1321 (2002)	
ED	1087	Llave, C., et al., "Virus-Encoded Suppressor of Posttranscriptional Gene Silencing Targets a Maintenance Step in the Silencing Pathway," PNAS, Vol. 97, No. 24, pp. 13401-13406 (2000)	
ED	1124	Novina, C., et al., "siRNA-Directed Inhibition of HIV-1 Infection," Nature Medicine, Vol. 8, No. 7, pp. 681-686 (2002)	
ED	1167	Provost, P., et al., "Ribonuclease Activity and RNA Binding of Recombinant Human Dicer," EMBO Journal, Vol. 21, No. 21, pp. 5864-5874 (2002)	
ED	1171	Pomerantz, R., "RNA Interference Meets HIV-1: Will Silence be Golden?" Nature Medicine, Vol. 8, No. 7, pp. 659-660 (2002)	
ED	1177	Ryo, A., et al., "Serial Analysis of Gene Expression in HIV-1 Infected T Cell Lines," FEBS Letters 462, pp. 182-186 (1999)	

Examiner Signature	/Eric Dejong/	Date Considered	.02/21/2007
-----------------------	---------------	--------------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/604,944
				Filing Date	August 28, 2003
				First Named Inventor	I. Bentwich
				Group Art Unit	1631
				Examiner Name	Dejong, Eric S.
Sheet	2	of	3	Attorney Docket Number	06087.0300.CPUS08

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
ED	1202	Smith, N., et al., "Total Silencing by Intron-Spliced Hairpin RNAs," Nature, Vol. 407, pp. 319-320 (2000)	
ED	1254	Waterhouse, P., et al., "Virus Resistance and Gene Silencing in Plants can be Induced by Simultaneous Expression of Sense and Antisense RNA," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 13959-13964 (1998)	
ED	1303	Ayash-Rashkovsky, M., et al., "Generation of Th1 Immune Responses to Inactivated, gp120-Depleted HIV-1 in Mice with a Dominant Th2 Biased Immune Profile via Immunostimulatory Oligonucleotides-Relevance to AIDS Vaccines in Developing Countries," Vaccine Vol. 20, pp. 2684-292 (2002)	
ED	1356	Jacque, J., et al., "Modulation of HIV-1 Replication by RNA Interference," Nature, Vol. 418, pp. 435-438 (2002)	
ED	1404	Merkle, I., et al., "Biological Significance of a Human Enterovirus B-Specific RNA Element in the 3' Nontranslated Region," Journal of Virology, Vol. 76, No. 19, pp. 9900-9909 (2002)	
ED	1420	Schramke, V., et al., "Hairpin RNAs and Retrotransposon LTRs Effect RNAi and Chromatin-Based Gene Silencing," Science, Vol. 301, pp. 1069-1074 (2003)	
ED	1424	Ryo, A., et al., "Identification and Characterization of Differentially Expressed mRNAs in HIV Type 1-Infected Human T Cells," Aids Research and Human Retroviruses, Vol. 16, No. 10, pp. 995-1005 (2000)	
ED	1441	Ambros, V., "MicroRNAs: Tiny Regulators with Great Potential," Cell, Vol. 107, pp. 823-826 (2001)	
ED	1477	Ambros, V., "MicroRNA Pathways in Flies and Worms: Growth, Death, Fat, Stress, and Timing," Cell, Vol. 113, pp. 673-676 (2003)	
ED	1449	Reinhart, B., et al., "The 21-Nucleotide <i>let-7</i> RNA Regulates Developmental Timing in <i>Caenorhabditis Elegans</i> ," Nature, Vol. 403, pp. 901-906 (2000)	
ED	1468	Lagos-Quintana, M., et al., "Identification of Novel Genes Coding for Small Expressed RNAs," Science, Vol. 294, pp. 853-858 (2001)	

Examiner Signature	/Eric Dejong/	Date Considered	02/21/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/604,944
				Filing Date	August 28, 2003
				First Named Inventor	I. Bentwich
				Group Art Unit	1631
				Examiner Name	Dejong, Eric S.
Sheet	3	of	3	Attorney Docket Number	06087.0300.CPUS08

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
ED	1485	Lee, N., et al., "Expression of Small Interfering RNAs Targeted Against HIV-1 <i>rev</i> Transcripts in Human Cells," Nature Biotechnology, Vol. 19, pp. 500-505 (2002)	
ED	1486	Morel, J., et al., "Fertile Hypomorphic ARGONAUTE (ago1) Mutants Impaired in Post-Transcriptional Gene Silencing and Virus Resistance," The Plant Cell, Vol. 14, pp. 629-639 (2002)	
ED	1622	Zhang, M., "Large-Scale Gene Expression Data Analysis: A New Challenge to Computational Biologists," Genome Research, Vol. 9, pp. 681-688 (1999)	

Examiner Signature	/Eric Dejong/	Date Considered	02/21/2007
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.